Opis projektu
Bliższe spojrzenie na leczenie oczu i zaawansowane interwencje chirurgiczne
Uszkodzenie wzroku jest główną przyczyną niepełnosprawności. W Europie średnio 1 na 30 osób doświadcza utraty wzroku. W związku z tym jednym z głównych priorytetów są dzisiaj choroby oczy. Jednak arsenał dostępnych środków ogranicza się do leków tradycyjnych i to pomimo znacznych postępów w leczeniu farmakologicznym. Zespół finansowanego przez UE projektu DYE-LIGHT zbada nowe sposoby na dostarczanie bioterapeutyków i przeprowadzanie zabiegów chirurgicznych oczu. Wykraczając poza obecne metody, które obejmują krople do oczu i zastrzyki, projekt rozważy zastosowanie laserów impulsowych o znacznie niższych poziomach energii niż obecnie stosowane w chirurgii oka w połączeniu z nanokapsułkowanymi barwnikami używanymi przez chirurgów do barwienia tkanek.
Cel
Ocular diseases affect the quality of life of millions of patients. Despite improvements in pharmacological treatments, the arsenal of medications to treat severe ocular diseases today remains rather restricted to traditional drugs. Use of most modern biotherapeutics like proteins and nucleic acids, could be a major step forward. However, current ways of administration such as eye drops and intravitreal injections, are no longer sufficient to deliver these drugs to most targets in the eye. Therefore, novel concepts allowing biotherapeutics to safely overcome ocular barriers are of high interest. In ocular surgery, pulsed-lasers (P-Ls) are used for ‘tissue cutting’, though safety concerns remain. DYE-LIGHT hypothesizes that strategies which would allow the use of P-Ls in the eye at much lower energy than today, could considerably improve safety and pave the way for both novel ocular therapies and advanced surgical interventions. DYE-LIGHT will explore vital dyes, as used by ocular surgeons to stain tissues, as photosensitizers. DYE-LIGHT follows the recent observation that P-L irradiation of ocular dyes can result in the formation of water vapor nanobubbles (‘dye-based nanobubbles’) and thermophoretic transport (‘dye-based thermophoresis’). Interestingly, these biophysical phenomena occur at a laser energy that is ~ 1000 times less than a P-L alone. As compared to free dyes, dyes encapsulated in nanocarriers are expected to penetrate less into the retina, which might improve safety. Therefore, focus in DYE-LIGHT will be on nano-encapsulated ocular dyes. DYE-LIGHT will explore the potential of dye-based nanobubbles for delivery of nucleic acids in the corneal endothelium and for spatial selective vitreolysis in the eye. Finally, DYE-LIGHT will explore dye-based thermophoresis for controlled transport of nanomedicines injected in the vitreous towards the retina. If successful, this might open new perspectives to improve the efficacy of retinal drug and gene delivery.
Dziedzina nauki
- natural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acids
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologynanomedicine
- medical and health sciencesclinical medicineophthalmology
- medical and health sciencesclinical medicinesurgerysurgical procedures
Słowa kluczowe
Program(-y)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Temat(-y)
System finansowania
HORIZON-ERC - HORIZON ERC GrantsInstytucja przyjmująca
9000 Gent
Belgia